# US 2005/0232871 A1 · Use of compounds in a dry powder inhaler

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0232871 A1
- Document ID: US20050232871A1
- Status: Published application
- Kind: A1
- Application number: 11/152,741
- Filed: 2005-06-13
- Published: 2005-10-20
- Earliest claimed: 2001-09-12
- Inventors: Michael Humphrey; Paul Miller; Michael Shepherd
- Web page: https://patentgrep.com/patent/US20050232871A1

## CPC

- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61M 13/00: Insufflators for therapeutic or disinfectant purposes {, i.e. devices for blowing a gas, powder or vapour into the body (hand-held units in which gas flow is produced by muscular energy at the moment of use B05B11/062)}
- A61M 15/00: Inhalators {(drug delivery in endotracheal tubes A61M16/04)}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/14: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to an inhaled formulation comprising a compound selected from a particular class of 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridines which is capable of delivering the compound as fine, solid particles to the lung and the use of such a formulation in the treatment of certain diseases such as respiratory diseases. By the use of such formulations, it is possible to eliminate the unwanted cough response associated with the use of these compounds in solution metered dose inhalers, which response can prevent the administration of a therapeutically effective dose and, in the long term, undermine patient compliance.

## Claims

### Claim 1

An inhaled formulation comprising a compound of the formula (I)
or a pharmaceutically acceptable salt thereof; wherein
R1 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C2-C4)alkenyl, phenyl, dimethylamino, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl(C1-C3)alkyl or (C1-C6)acyl wherein the alkyl, phenyl or alkenyl groups may be substituted with up to two hydroxy, (C1-C3)alkyl, or trifluoromethyl groups, or up to three halogens;
R2 and R3 are each independently selected from the group consisting of hydrogen, (C1-C14)alkyl, (C1-C7)alkoxy(C1-C7)alkyl, (C2-C14)alkenyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C2)alkyl, a saturated or unsaturated (C4-C7)heterocyclic(CH2)n group wherein n is 0, 1 or 2, containing as the heteroatom one or two of the group consisting of oxygen, sulphur, sulphonyl, nitrogen and NR4 wherein R4 is hydrogen or (C1-C4)alkyl; or a group of the formula
wherein a is an integer from 1 to 5; b and c are 0 or 1; R5 is hydrogen, hydroxy, (C1-C5)alkyl, (C2-C5)alkenyl, (C1-C5) alkoxy, (C3-C6)cycloalkoxy, halogen, trifluoromethyl, CO2R6, CONR6R7, NR6R7, NO2 or SO2NR6R7 wherein R6 and R7 are each independently hydrogen or (C1-C4)alkyl; wherein Z is oxygen, sulphur, SO2, CO or NR8 wherein R8 is hydrogen or (C1-C4)alkyl; and Y is (C1-C5)alkylene or (C2-C6)alkenyl optionally substututed with up to two (C1-C7)alkyl or (C3-C7)cycloalkyl groups; wherein each of the alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic groups may be substituted with one to fourteen of the group consisting of (C1-C2)alkyl, trifluoromethyl or halogen; and
R9 and R10 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C6-C10)aryl and (C6-C10)aryloxy;
characterised in that the formulation is capable of delivering the compound as fine, solid particles to the lung.

### Claim 2 (depends on 1)

An inhaled formulation according to claim 1 wherein each of the alkyl, alkenyl, cycloalkyl, alkoxyalkyl and heterocyclic groups may be substituted with 1 to 5 of the group consisting of (C1-C2)alkyl, trifluoromethyl and hydrogen.

### Claim 3 (depends on 1)

An inhaled formulation according to claim 1 wherein R1 is methyl, ethyl or isopropyl.

### Claim 4 (depends on 1)

An inhaled formulation according to claim 1 wherein R3 is (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C2)alkyl or phenyl optionally substituted with 1 or 2 of the group consisting of hydrogen, hydroxy, (C1-C5)alkyl, (C2-C5)alkenyl, (C1-C5)alkoxy, halogen, trifluoromethyl, CO2R6, CONR6R7, NR6R7, NO2 or SO2NR6R7 wherein R6 and R7 are each independently hydrogen or (C1-C4)alkyl.

### Claim 5 (depends on 1)

An inhaled formulation according to claim 1 wherein the compound of the formula (I) is selected from:
9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
3-(tert-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9H-pyrazolo[3,4-c]1,2,4-triazolo[4,3α]pyridine;
3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9H-pyrazolo[3,4c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine; and
5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine;
and the pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 1)

An inhaled formulation according-to claim 1 wherein the compound of the formula (I) is 3-(tert-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine.

### Claim 7 (depends on 1)

An inhaled formulation according to claim 1 wherein the compound of the formula (I) is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9H-pyrazolo[3,4-c]1,2,4-triazolo[4,3-α]pyridine.

### Claim 8 (depends on 1)

An inhaled formulation according to claim 1 wherein the compound of the formula (I) has an aqueous solubility at physiological pH of less than 0.15 mg/ml.

### Claim 9 (depends on 8)

An inhaled formulation according to claim 8 wherein the compound of the formula (I) has an aqueous solubility at physiological pH of less than 0.05 mg/ml.

### Claim 10 (depends on 1)

An inhaled formulation according to claim 1 wherein the fine, solid drug particles have a size distribution of 90% less than 10 micrometers in diameter and 50% less than 5 micrometers in diameter.

### Claim 11 (depends on 10)

An inhaled formulation according to claim 10 wherein the fine, solid drug particles have a size distribution of 90% less than 6 micrometers in diameter and 50% less than 3 micrometers in diameter.

### Claim 12 (depends on 1)

An inhaled formulation according to claim 1 wherein the fine, solid particles are delivered to the lung by a dry powder inhaler.

### Claim 13 (depends on 12)

An inhaled formulation according to claim 12 wherein the dry powder blend comprises lactose, preferably in its monohydrated form.

### Claim 14 (depends on 1)

An inhaled formulation according to claim 1 wherein the fine, solid particles are delivered by a suspension metered dose inhaler, a suspension atomiser or a suspension nebuliser.

### Claim 15 (depends on 1)

An inhaled formulation according to claim 1 wherein the fine, solid particles consist of microspheres, said microspheres comprising poly(D,L-lactic-co-glycolic acid).

### Claim 16 (depends on 1)

An inhaled formulation according to claim 1 for use as a medicament.

### Claim 17 (depends on 1)

The use of an inhaled formulation according to claim 1 in the manufacture of a medicament for the treatment of a disease treatable by the inhibition of PDE4.

### Claim 18 (depends on 17)

The use according to claim 17, wherein the disease is a respiratory disease.

### Claim 19 (depends on 18)

The use according to claim 18 wherein the respiratory disease is asthma or chronic obstructive pulmonary disease.

### Claim 20 (depends on 1)

A method of treatment of a disease treatable by the inhibition of PDE4 comprising the administration of an inhaled formulation according to claim 1 to a mammal.

### Claim 21 (depends on 20)

A method of treatment according to claim 20 wherein the disease is a respiratory disease.

### Claim 22 (depends on 21)

A method of treatment according to claim 21 wherein the respiratory disease is asthma or chronic obstructive pulmonary disease.

### Claim 23 (depends on 1)

The use of a compound of the formula (I), as defined in claim 1, having an aqueous solubility at physiological pH of less than 0.15 mg/ml in the manufacture of a medicament for administration by inhalation, characterised in that said medicament is in the form of a dry powder inhaler or other device capable of delivering low solubility particles.

### Claim 24 (depends on 23)

Use according to claim 23 wherein said medicament is in the form of a device other than a dry powder inhaler which is capable of delivering low solubility particles, which device is a suspension metered dose inhaler or a device capable of delivering liposomes, micronised/engineered particles, or microspheres.

### Claim 25 (depends on 24)

Use according to claim 24 wherein said device is a device capable of delivering microspheres, which microspheres comprise poly(D,L-lactic-co-glycolic acid).

### Claim 26 (depends on 23)

A dry powder inhaler containing a compound of formula (I) as described in claim 23.

### Claim 27 (depends on 23)

A device other than a dry powder inhaler which is capable of delivering low solubility particles, which device contains a compound of formula (I) as described in claim 23.
